Search Results

AngioDynamics, Inc. (NASDAQ: ANGO) today announced European CE Mark approval of the AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary arteries and for the treatment of pulmonary embolism (PE).

AngioDynamics, Inc. announced that the United States Food and Drug Administration has cleared the AlphaVac F1885 System for the treatment of pulmonary embolism, enhancing its utility in critical medical scenarios such as PE.

AngioDynamics, Inc. (NASDAQ: ANGO) today announced that results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) were presented at The Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions hosted in Long Beach, California on May 3, 2024.

AngioDynamics, Inc. announced that it has completed the sale of its PICC and Midline product portfolios to Spectrum Vascular, an innovative medical device company focused on vascular access and medication management, for up to $45 million in cash.

AngioDynamics, Inc. (NASDAQ: ANGO) today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Virtual Healthcare MedTech & Services Conference at 12:40 p.m. ET on Tuesday, March 12, 2024.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market open on Thursday, April 4, 2024.

AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease.